Company Projected Revenue: Stoke Therapeutics Inc (STOK)

Public company logo of Stoke Therapeutics (STOK)

Stoke Therapeutics (STOK) develops unique RNA-based drugs for rare pathologies, which will grant the company exceptional pricing power. The lack of market alternatives for Dravet syndrome therapy strengthens its dominance. The sales volume forecast visualizes this trend, where 0.03 determines the current status of the parameter. Meanwhile, the company relies on external contractors for conducting clinical trials and batch production.

STOK - Stoke Therapeutics Projected Sales Volume over the range 07/04/2022 - 11/16/2026

Summary analytical data breakdowns for Stoke Therapeutics (STOK)

- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:Stoke Therapeutics STOK
Brand item of Stoke Corp

This indicator captures market expectations for future revenue by transforming capitalization into a specific cash equivalent of projected sales. By analyzing the expected sales dynamics of Stoke Therapeutics (STOK), an investor can assess the extent to which current successes in RNA therapy for epilepsy are priced into the asset's value, allowing for a comparison between the rate of capital expenditure and the business's fundamental growth potential.

Key competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume